The firm also received approval from the Singapore Health Sciences Authority to market the Unyvero blood culture cartridges.
The system will enable testing direct from a tube of blood using peptide nucleic acids-based methods to improve specificity.
The funding will accelerate development of the firm's RaPID diagnostic platform to identify pathogens and drug resistance directly from blood.
The proposed diagnostic platform will be able to identify and determine resistance of bloodstream infections within three hours.
Running on the Biocartis Idylla platform, Immunexpress' Septicyte test will detect sepsis in patients in as little as an hour.
In the longer term, the two firms plan to use PlexBio's multiplexing technology to develop a full menu of infectious disease assays.
Biocartis will help develop and commercialize Immunexpress' Septicyte test to run on the Idylla platform.
Its CEO said that although a hospital screening test for sepsis is a focus, a fever test that informs about antibiotic use could be available sooner.
BioMérieux sees Qvella's system as complementary to its BioFire FilmArray and will consider adopting Qvella's sample treatment technology.
New investor BioMérieux will explore collaborative opportunities using Qvella's sample treatment technology in complementary markets.
Mice in New York harbor both antibiotic-resistant bacteria and novel viruses, according to a new analysis of their fecal microbiomes.
Human Heredity and Health in Africa Initiative has issued guidelines for genomic research in the region, according to Nature News.
The Associated Press reports that an ethicist predicts that prenatal diagnosis and other advances will lead to more choices being available to prospective parents.
In Genome Biology this week: approach to analyze alternative polyadenylation, algorithm to predict transcriptomic structural variations, and more.
